Overview
Immatics Q3 collaboration revenue misses analyst expectations, reflecting a significant year-over-year decline
Net income for Q3 misses analyst estimates, with a larger loss than expected
Company advances PRAME cell therapies and bispecifics, with ongoing trials and future market plans
Outlook
Immatics plans BLA submission for anzu-cel in 1H 2027, launch in 2H 2027
Company advancing IMA402 PRAME Bispecific into Phase 1b trials in 2026
Cash position expected to support operations into 2H 2027
Result Drivers
REVENUE DECLINE - The decrease is mainly the result of a one-time revenue associated with the termination of the IMA401 collaboration by Bristol Myers Squibb
CASH POSITION - Immatics reported cash and financial assets of $505.8 mln as of September 30, 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Collaboration Revenue | Miss | EUR 5.19 mln | EUR 10.66 mln (6 Analysts) |
Q3 Net Income | Miss | -EUR 50.55 mln | -EUR 47.82 mln (5 Analysts) |
Q3 Operating Income | Miss | -EUR 54.63 mln | -EUR 49.82 mln (6 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Immatics NV is $16.00, about 36.3% above its November 14 closing price of $10.20
Press Release: ID:nGNE3FF5CL
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments